Папиллярная микрокарцинома щитовидной железы

По данным ВОЗ, папиллярная микрокарцинома определяется как вариант папиллярного рака щитовидной железы (РЩЖ), меньше или равный 1 см в диаметре. На папиллярную микрокарциному приходится до 30% всего папиллярного РЩЖ. В обзоре представлены современные данные о хирургическом лечении, радиойодтерапии, наблюдении пациентов с папиллярной микрокарциномой щитовидной железы.

папиллярная микрокарцинома, хирургическое лечение, радиойодтерапия

1. Pacini F. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787-803. doi: 10.1530/eje.1.02158

2. Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes & Control. 2008;20(5):525-531. doi: 10.1007/s10552-008-9260-4

3. Cordioli MICV, Canalli MHBS, Coral MHC. Increase incidence of thyroid cancer in Florianopolis, Brazil: Comparative study of diagnosed cases in 2000 and 2005. Arquivos Brasileiros de Endocrinologia & Metabologia. 2009;53(4). doi: 10.1590/s0004-27302009000400011

4. Leenhardt L, Grosclaude P, Chérié-Challine L. Increased incidence of thyroid carcinoma in France: A true epidemic or thyroid nodule management effects? Report from the french thyroid cancer committee. Thyroid. 2004;14(12):1056-1060. doi: 10.1089/thy.2004.14.1056

5. Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: A study of 900 cases observed in a 60-year period. Surgery. 2008;144(6):980-988. doi: 10.1016/j.surg.2008.08.035

6. Lee J, Rhee Y, Lee S, et al. Frequent, aggressive behaviors of thyroid microcarcinomas in korean patients. Endocr J. 2006;53(5): 627-632. doi: 10.1507/endocrj.K06-013

7. Lin HW, Bhattacharyya N. Survival impact of treatment options for papillary microcarcinoma of the thyroid. Laryngoscope. 2009;119(10):1983-1987. doi: 10.1002/lary.20617

8. Zengi A, Karadeniz M, Erdogan M, et al. Does Chernobyl accident have any effect on thyroid cancers in Turkey? A retrospective review of thyroid cancers from 1982 to 2006. Endocr J. 2008;55(2):325-330. doi: 10.1507/endocrj.K08E-007

9. Lin J-D. Increased incidence of papillary thyroid microcarcinoma with decreased tumor size of thyroid cancer. Med Oncol. 2009;27(2):510-518. doi: 10.1007/s12032-009-9242-8

10. Roti E, Degli Uberti EC, Bondanelli M, et al. Thyroid papillary microcarcinoma: A descriptive and meta-analysis study. Eur J Endocrinol. 2008;159(6):659-673. doi: 10.1530/eje-07-0896

11. Wang TS, Goffredo P, Sosa JA, et al. Papillary thyroid microcarcinoma: An over-treated malignancy? World J Surg. 2014;38(9): 2297-2303. doi: 10.1007/s00268-014-2602-3

12. Greene FL, Sobin LH. The tnm system: Our language for cancer care. J Surg Oncol. 2002;80(3):119-120. doi: 10.1002/jso.10114

13. Румянцев П.О., Ильин А.А., Румянцева У.В., Саенко В.А. Рак щитовидной железы. - М.: ГЭОТАР-Медиа; 2009. [Rumyantsev PO, Il’in AA, Rumyantseva UV, Saenko VA. Rak shchitovidnoi zhelezy. Moscow: GEOTAR-Media; 2009. (In Russ).]

14. De Lellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004.

15. Nasir A, Chaudhry AZ, Gillespie J, Kaiser HE. Papillary microcarcinoma of the thyroid: a clinico-pathologic and prognostic review. In Vivo. 2000;14 (2):367-376.

16. Шулутко А.М., Семиков В.И., Грязнов С.Е., и др. Клиническое значение, диагностика и лечение дифференцированной микрокарциномы ЩЖ. // Хирургия. Журнал им. Н.И. Пирогова. - 2007. - №12 - C.1-15. [Shulutko AM, Semikov VI, Gryaznov SE, at al. Klinicheskoe znachenie, diagnostika i lechenie differentsirovannoi mikrokartsinomy ShchZh. Khirurgiya. Zhurnal im. N.I. Pirogova. 2007;12:1-15. (In Russ).]

17. Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: A surgical perspective. Cancer Treatment Rev. 2005;31(6): 423-438. doi: 10.1016/j.ctrv.2005.04.009

18. Karatzas T, Vasileiadis I, Kapetanakis S, et al. Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma. Am J Surg. 2013; 206(4):586-593. doi: 10.1016/j.amjsurg.2013.02.008

19. Kucuk NO, Tari P, Tokmak E, et al. Treatment for microcarcinoma of the thyroid??? Clinical experience. Clin Nucl Med. 2007;32(4): 279-281. doi: 10.1097/01.rlu.0000257272.90126.3d

20. Schönberger J, Marienhagen J, Agha A, et al. Papillary microcarcinoma and papillary cancer of the thyroid £1 cm. Nuklearmedizin. 2007. doi: 10.1160/nukmed-0059

21. Tuttle RM, Ball DW, Byrd D, et al. Thyroid Carcinoma. J Natl Compr Canc Netw. 2010;8:1228-1274.

22. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic” - screening and overdiagnosis. New Engl J Med. 2014; 371(19):1765-1767. doi: 10.1056/NEJMp1409841

23. Udelsman R, Zhang Y. The epidemic of thyroid cancer in the united states: The role of endocrinologists and ultrasounds. Thyroid. 2014;24(3):472-479. doi: 10.1089/thy.2013.0257

24. Hughes DT, Haymart MR, Miller BS, et al. The most commonly occurring papillary thyroid cancer in the united states is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;21(3):231-236. doi: 10.1089/thy.2010.0137

25. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the united states by demographic and tumor characteristics, 1980-2005. Cancer Epidemiology Biomarkers & Prevention. 2009; 18(3):784-791. doi: 10.1158/1055-9965.epi-08-0960

26. Davies L, Welch HG. Increasing incidence of thyroid cancer in the united states, 1973-2002. JAMA. 2006;295(18):2164. doi: 10.1001/jama.295.18.2164

27. Akslen LA, Livolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer. 2000;88(8):1902-1908. doi: 10.1002/(sici)1097-0142(20000415)88:8<1902::aid-cncr20>3.0.co;2-y

28. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11): 1167-1214. doi: 10.1089/thy.2009.0110

29. Rouxel A, Hejblum G, Bernier M-O, et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2004;89(11):5362-5368. doi: 10.1210/jc.2003-032004

30. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: A european perspective. Eur J Endocrinol. 2004;150(2):105-112. doi: 10.1530/eje.0.1500105

31. Wenig BM, Thompson LDR, Adair CF, et al. Thyroid papillary carcinoma of columnar cell type. Cancer. 1998;82(4):740-753. doi: 10.1002/(sici)1097-0142(19980215)82:4<740::aid-cncr18>3.0.co;2-y

32. Ardito G, Revelli L, Giustozzi E, et al. Aggressive papillary thyroid microcarcinoma. Clin Nucl Med. 2013;38(1):25-28. doi: 10.1097/RLU.0b013e318279bc65

33. Shaha A. Treatment of thyroid cancer based on risk groups. J Surg Oncol. 2006. 94; 8:683-691. PMID: 17131422

34. Диагностика и лечение дифференцированного РЩЖ. Нац. клин. реком., принятые на XI Рос. онкол. конгр. и IV Всерос. тиреоидол. конгр. - М.: Никомед; 2007. [Diagnostika i lechenie differentsirovannogo RShchZh. Nats. klin. rekom., prinyatye na XI Ros. onkol. kongr. i IV Vseros. tireoidol. kongr. - Moscow: Nikomed; 2007. (In Russ).]

35. Cooper DS, Doherty GM, Haugen BR, et al. Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-1214. doi: 10.1089/thy.2009.0110

36. Morrison S, Suh H, Hodin R. The surgical management of thyroid cancer. Rambam Maimonides Medical Journal. 2014;5(2):e0008. doi: 10.5041/rmmj.10142

37. Takami H, Ito Y, Okamoto T, et al. Revisiting the guidelines issued by the japanese society of thyroid surgeons and japan association of endocrine surgeons: A gradual move towards consensus between japanese and western practice in the management of thyroid carcinoma. World J Surg. 2014;38(8):2002-2010. doi: 10.1007/s00268-014-2498-y

38. Zafon C, Baena JA, Castellví J, et al. Differences in the form of presentation between papillary microcarcinomas and papillary carcinomas of larger size. J Thyroid Res. 2011;2011:1-5. doi: 10.4061/2011/639156

39. Lee KJ, Cho YJ, Kim JG, et al. How many contralateral papillary thyroid carcinomas can be missed? World J Surg. 2013;37(4): 780-785. doi: 10.1007/s00268-013-1913-0

40. Pelizzo MR, Merante Boschin I, Toniato A, et al. Papillary thyroid microcarcinoma. Long-term outcome in 587 cases compared with published data. Minerva Chir. 2007; 62(5):315-325.

41. George H, Sakorafas S, Giotakis J, et al. Papillary thyroid microcarcinoma: A surgical perspective Cancer Treatment Reviews October 2005:423-438.

42. Li Z, Qu XC, Cheng B. The characteristics of papillary thyroid cancer lymph node metastasis and the clinical significance of central region cervical lymph node dissection. Zhonghua Wai Ke Za Zhi. 2008; 46(18):1407-1409.

43. Caliskan M, Park JH, Jeong JS, et al. Role of prophylactic ipsilateral central compartment lymph node dissection in papillary thyroid microcarcinoma. Endocrin J. 2012;59(4):305-311. doi: 10.1507/endocrj.EJ11-0366

44. Hyun SM, Song HY, Kim SY, et al. Impact of combined prophylactic unilateral central neck dissection and hemithyroidectomy in patients with papillary thyroid microcarcinoma. Ann Surg Oncol. 2011;19(2):591-596. doi: 10.1245/s10434-011-1995-6

45. Kim B-Y, Jung C-H, Kim J-W, et al. Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Yonsei Medical Journal. 2012;53(5):924. doi: 10.3349/ymj.2012.53.5.924

46. Zeng R-C, Li Q, Lin K-L, et al. Predicting the factors of lateral lymph node metastasis in papillary microcarcinoma of the thyroid in eastern china. Clin Translati Oncol. 2012;14(11): 842-847. doi: 10.1007/s12094-012-0875-2

47. Zhang L, Wei W-J, Ji Q-H, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: A study of 1066 patients. J Clin Endocrinol Metab. 2012;97(4):1250-1257. doi: 10.1210/jc.2011-1546

48. Zhou Y-L, Gao E-L, Zhang W, et al. Factors predictive of papillary thyroid micro-carcinoma with bilateral involvement and central lymph node metastasis: A retrospective study. World J Surg Oncol. 2012;10(1):67. doi: 10.1186/1477-7819-10-67

49. Lee YS, Lim H, Chang H-S, et al. Papillary thyroid microcarcinomas are different from latent papillary thyroid carcinomas at autopsy. J Korean Med Sci. 2014;29(5):676. doi: 10.3346/jkms.2014.29.5.676

50. Chéreau N, Buffet C, Trésallet C, et al. Does extracapsular extension impact the prognosis of papillary thyroid microcarcinoma? Ann Surg Oncology. 2014;21(5):1659-1664. doi: 10.1245/s10434-013-3447-y

51. Page C, Biet A, Boute P, et al. ‘Aggressive papillary’ thyroid microcarcinoma. Eur Arch Oto-Rhino-Laryngol. 2009;266(12):1959-1963. doi: 10.1007/s00405-009-0952-5

52. Buffet C, Golmard JL, Hoang C, et al. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. Eur J Endocrinol. 2012. doi: 10.1530/eje-12-0105

53. Riss JC, Peyrottes I, Chamorey E, et al. Prognostic impact of tumour multifocality in thyroid papillary microcarcinoma based on a series of 160 cases. Eur Ann Otorhinolaryngol, Head and Neck Dis. 2012;129(4):175-178. doi: 10.1016/j.anorl.2011.11.003

54. Dralle H, Machens A. Primary surgery for differentiated thyroid cancer in the new millennium. J Endocrinol Invest. 2012; 35(6 Suppl): 10-15.

55. Ito Y, Tomoda C, Uruno T, et al. Papillary microcarcinoma of the thyroid: How should it be treated? World J Surgery. 2004;28(11):1115-1121. doi: 10.1007/s00268-004-7644-5

56. Lee J, Park JH, Lee C-R, et al. Long-term outcomes of total thyroidectomy versus thyroid lobectomy for papillary thyroid microcarcinoma: Comparative analysis after propensity score matching. Thyroid. 2013;23(11):1408-1415. doi: 10.1089/thy.2012.0463

57. Pacini F. Management of papillary thyroid microcarcinoma: Primum non nocere! J Clin Endocrinol Metab. 2013;98(4):1391-1393. doi: 10.1210/jc.2013-1634

58. Kim MJ, Kim E-K, Kim BM, et al. Thyroglobulin measurement in fine-needle aspirate washouts: The criteria for neck node dissection for patients with thyroid cancer. Clin Endocrinol. 2009; 70(1):145-151. doi: 10.1111/j.1365-2265.2008.03297.x

59. Lin J-D, Lin K-J, Chao T-C, et al. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than t1n0m0. Radiother Oncol. 2008;89(1):97-104. doi: 10.1016/j.radonc.2008.05.011

60. Mihailovic J, Stefanovic L, Malesevic M. Differentiated thyroid carcinoma with distant metastases: Probability of survival and its predicting factors. Cancer Biotherapy & Radiopharmaceuticals. 2007;22(2):250-255. doi: 10.1089/cbr.2006.313

61. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447-1463. doi: 10.1210/jcem.86.4.7407

62. Sawka AM, Thephamongkhol K, Brouwers M, et al. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89(8):3668-3676. doi: 10.1210/jc.2003-031167

63. Mallick U, Harmer C, Hackshaw A, et al. Iodine or not (ion) for low-risk differentiated thyroid cancer: The next uk national cancer research network randomised trial following hilo. Clin Oncol. 2012;24(3):159-161. doi: 10.1016/j.clon.2012.01.001

64. Mazzaferri EL, Jhiang SM. Differentiated thyroid cancer: long-term impact of initial therapy. Trans. of the Am Clin Climatol Assoc. 1994;106:151-170.

65. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: A retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992;75(3):714-720. doi: 10.1210/jcem.75.3.1517360

66. Taylor T. Outcome after treatment of high-risk papillary and non-hurthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998; 129(8):622. doi: 10.7326/0003-4819-129-8-199810150-00007

67. Gallicchio R, Giacomobono S, Capacchione D, et al. Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation? Endocrine. 2013;44(2):426-433. doi: 10.1007/s12020-013-9935-9

68. Schlumberger M, Charbord P, Fragu P, et al. Circulating thyroglobulin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: Relationship to serum thyrotropin levels. J Clin Endocrinol Metab. 1980;51(3):513-519. doi: 10.1210/jcem-51-3-513

69. Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006;91(3):878-884. doi: 10.1210/jc.2005-2064

70. Hänscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47(4):648-654.

71. Rosario PW, Borges MaR, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med. 2008;49(11):1776-1782. doi: 10.2967/jnumed.108.050591

72. Tala Jury HP, Castagna MG, Fioravanti C, et al. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab. 2010;95(1):230-237. doi: 10.1210/jc.2009-1624

73. Ma C, Xie J, Liu W, et al. Recombinant human thyrotropin (rhtsh) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. 2010. doi: 10.1002/14651858.cd008302

74. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. New Engl J Med. 2012;366(18):1674-1685. doi: 10.1056/NEJMoa1109589

75. Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. New Engl J Med. 2012;366(18):1663-1673. doi: 10.1056/NEJMoa1108586

76. Iorcansky S, Herzovich V, Qualey RR, et al. Serum thyrotropin (tsh) levels after recombinant human tsh injections in children and teenagers with papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6553-6555. doi: 10.1210/jc.2005-1550

77. Luster M, Handkiewicz-Junak D, Grossi A, et al. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: A multicenter retrospective study. J Clin Endocrinol Metab. 2009;94(10):3948-3953. doi: 10.1210/jc.2009-0593

78. Maxon HR, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990;19(3):685-718.

79. Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med. 2006;47(10):1587-1591.

80. Pacini F. Post-surgical use of radioiodine (131i) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: A consensus report. Eur J Endocrinol. 2005;153(5):651-659. doi: 10.1530/eje.1.02014

81. Randolph GW, Daniels GH. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid. Thyroid. 2002;12(11):989-996. doi: 10.1089/105072502320908321

82. Giovanella L, Maffioli M, Ceriani L, et al. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma. Clin Chemistry Labor Med. 2009;47(8). doi: 10.1515/cclm.2009.216

83. Malandrino P, Latina A, Marescalco S, et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab. 2011;96(6):1703-1709. doi: 10.1210/jc.2010-2695

84. Castagna MG, Tala Jury HP, Cipri C, Belardini V, et al. The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest. 2011;34(8):e219-223. doi: 10.3275/7571.

85. Brassard M, Borget I, Edet-Sanson A, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: A prospective study on 715 patients. J Clin Endocrinol Metab. 2011; 96(5):1352-1359. doi: 10.1210/jc.2010-2708

86. Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant human thyrotropin (rhtsh)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhtsh-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab. 2008;93(1):76-81. doi: 10.1210/jc.2007-1404

87. Crocetti U, Durante C, Attard M, et al. Predictive value of recombinant human tsh stimulation and neck ultrasonography in differentiated thyroid cancer patients. Thyroid. 2008;18(10):1049-1053. doi: 10.1089/thy.2008.0160

88. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab. 2005;90(9):5047-5057. doi: 10.1210/jc.2005-0492

89. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, et al. Does an undetectable rhtsh-stimulated tg level 12 months after initial treatment of thyroid cancer indicate remission? Clin Endocrinol. 2011;74(1):111-117. doi: 10.1111/j.1365-2265.2010.03898.x

90. Pacini F, Mariotti S, Formica N, et al. Thyroid autoantibodies in thyroid cancer: Incidence and relationship with tumour outcome. Eur J Endocrinol. 1988;119(3):373-380. doi: 10.1530/acta.0.1190373

91. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: Prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83(4): 1121-1127. doi: 10.1210/jcem.83.4.4683

92. Chiovato L. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med. 2003; 139(5_Part_1):346. doi: 10.7326/0003-4819-139-5_Part_1-200309020-00010

93. Kim WG, Yoon JH, Kim WB, et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2008;93(12):4683-4689. doi: 10.1210/jc.2008-0962

94. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines taskforce. Thyroid. 2006;16(2):109-142. doi: 10.1089/thy.2006.16.109

95. Miyauchi A, Kudo T, Miya A, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011;21(7):707-716. doi: 10.1089/thy.2010.0355

96. Durante C, Montesano T, Attard M, et al. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: Is there a role for serum thyroglobulin measurement? J Clin Endocrinol Metab. 2012; 97(8):2748-2753. doi: 10.1210/jc.2012-1123

97. Hovens GC, Stokkel MP, Kievit J, et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92(7):2610-2615. doi: 10.1210/jc.2006-2566

98. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16(12):1229-1242. doi: 10.1089/thy.2006.16.122

99. Sugitani I, Fujimoto Y. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J Clin Endocrinol Metab. 2010; 95(10):4576-4583. doi: 10.1210/jc.2010-0161

100. Румянцев П.О., Коренев С.В., Румянцева У.В. Современные принципы терапии левотироксином после операции у больных высокодифференцированным РЩЖ. // Опухоли головы и шеи. - 2013. - №2 - С.5-8. [Rumyantsev PO, Korenev SV, Rumyantseva UV. Sovremennye printsipy terapii levotiroksinom posle operatsii u bol’nykh vysokodifferentsirovannym RShchZh. Opukholi golovy i shei. 2013;2:5-8. (In Russ.)]